An Introduction to Generative Drug Discovery
暫譯: 生成藥物發現入門
Ekins, Sean
- 出版商: CRC
- 出版日期: 2026-05-21
- 售價: $2,580
- 貴賓價: 9.5 折 $2,451
- 語言: 英文
- 頁數: 222
- 裝訂: Quality Paper - also called trade paper
- ISBN: 1032506253
- ISBN-13: 9781032506258
-
相關分類:
GAN 生成對抗網絡
海外代購書籍(需單獨結帳)
相關主題
商品描述
This book describes the state-of-the-art methods and applications for de novo design of drug candidates using generative chemistry models as well as the ethical aspects of this technology. It will provide a foundation for those new to the field as well as those that may already have some experience of its utility. With contributions from scientists in both academia and industry 'Introduction to Generative Drug Discovery' may represent one of the earliest if not the first book to focus on this topic.
- This book focuses on the latest advances in computational de novo drug discovery methods, also known as generative drug discovery
- This book will describe different state of the art applications of generative molecule design.
- The book describes ethical aspects of generative drug discovery technology.
- The mix of academic and industrial authors provides an array of applications of generative drug discovery.
- A future perspective of where these generative technologies may take us in drug discovery is described included self-driving labs.
商品描述(中文翻譯)
這本書描述了使用生成化學模型進行新藥候選物的設計的最先進方法和應用，以及這項技術的倫理方面。它將為新進入該領域的人士提供基礎，也適合那些已經對其實用性有一定經驗的人士。這本《生成藥物發現導論》匯集了來自學術界和業界的科學家的貢獻，可能是最早專注於這一主題的書籍之一。
- 本書專注於計算新藥發現方法的最新進展，也稱為生成藥物發現。
- 本書將描述生成分子設計的不同最先進應用。
- 本書描述了生成藥物發現技術的倫理方面。
- 學術界和工業界作者的混合提供了生成藥物發現的多種應用。
- 本書描述了這些生成技術在藥物發現中可能帶來的未來展望，包括自動駕駛實驗室。
作者簡介
Sean Ekins is founder and CEO of Collaborations Pharmaceuticals, Inc. (CPI) which is focused on using machine learning approaches for rare and neglected disease drug discovery. Sean graduated from the University of Aberdeen, receiving his M.Sc., Ph.D. in Clinical Pharmacology and D.Sc. in Science. He was a postdoctoral fellow at Eli Lilly, before working as a senior scientist at Pfizer and then returning to Eli Lilly. He went on to join several startup companies at increasingly senior levels. Since 2005 he has been awarded numerous grants as PI for a wide array of start-up companies totaling over $12.2M as well as performing as a consultant on others. Since 2016 he has additionally won over 20 additional grants from NIH and DOD (STTR/SBIR grants, R21, UH2 and R01) totaling over $21.2M for CPI. He has a passion for advancing new technologies for drug discovery and is a prolific collaborator. He has authored or co-authored over 370 peer reviewed papers, book chapters, edited 5 books on different aspects of drug discovery research and topics and written one book on winning grants. Coverage of his recent research has also appeared in the Economist, Financial Times, Washington Post, Wired, Scientific American, CNN and Netflix as well as several podcasts. When he is not writing he enjoys cycling and record collecting.
作者簡介(中文翻譯)
Sean Ekins 是 Collaborations Pharmaceuticals, Inc. (CPI) 的創辦人兼執行長，該公司專注於利用機器學習方法進行罕見病和被忽視疾病的藥物發現。Sean 畢業於阿伯丁大學，獲得臨床藥理學的碩士、博士學位及科學博士學位。他曾在 Eli Lilly 擔任博士後研究員，之後在 Pfizer 擔任高級科學家，然後再次回到 Eli Lilly。他隨後加入幾家初創公司，擔任越來越高級的職位。自 2005 年以來，他作為主要研究者 (PI) 獲得了多項資助，涉及多家初創公司，總金額超過 1220 萬美元，並且還擔任其他公司的顧問。自 2016 年以來，他還從 NIH 和 DOD 獲得了超過 20 項額外的資助（STTR/SBIR 資助、R21、UH2 和 R01），總金額超過 2120 萬美元，這些資助均用於 CPI。他熱衷於推進藥物發現的新技術，並且是一位多產的合作者。他已經撰寫或共同撰寫了超過 370 篇經過同行評審的論文、書籍章節，編輯了 5 本有關藥物發現研究和主題的書籍，並撰寫了一本關於獲取資助的書籍。他最近的研究也曾在《經濟學人》、《金融時報》、《華盛頓郵報》、《Wired》、《科學美國人》、《CNN》和 Netflix 以及幾個播客中報導。當他不在寫作時，他喜歡騎自行車和收集唱片。
